{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-019858","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.214787+00:00","generated_at":"2026-06-25T18:20:15.769383+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Trevi Q1 net loss $7.3M; Phase 2 CANAL shows 52% placebo-adjusted cough reduction; $55M financing closed","bullets":["Q1 2022 net loss $7.3M vs $8.4M prior year; R&D expenses $4.6M down from $5.6M.","Cash $29.1M at March 31; plus $55M gross from April private placement for Haduvio development.","Phase 2 CANAL interim (N=26): 77.3% reduction daytime cough vs 25.7% placebo (p<0.0001); enrollment ended early.","Full CANAL data expected Q3 2022; Phase 2b/3 PRISM (PN) top-line data expected Q2 2022.","Phase 2b/3 PRISM enrollment completed Jan 2022; data readout anticipated in current quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-019858","json":"https://secwatch.observer/filing/0001564590-22-019858.json","markdown":"https://secwatch.observer/filing/0001564590-22-019858.md","text":"https://secwatch.observer/filing/0001564590-22-019858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022019858/0001564590-22-019858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022019858/trvi-8k_20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:20:15.769383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}